Mizuho Lifts Corvus (CRVS) Price Target to $20 on Trial Data

Mizuho Raises Corvus Pharmaceuticals Target to $20

Mizuho has significantly increased its price target for Corvus Pharmaceuticals (NASDAQ:CRVS) to $20.00 from $13.00, representing a 50% boost. The firm maintained its Outperform rating, citing positive clinical trial results for the company's leading drug candidate, soquelitinib.

Strong Clinical Data Drives Optimism

The revised target follows updated Phase 1 data for soquelitinib (SQL), an oral ITK inhibitor developed for atopic dermatitis. Mizuho described the results as "outstanding," suggesting the drug could become a best-in-disease treatment within a market estimated at $50 billion.

Impact on CRVS Stock and Valuation

Mizuho named Corvus Pharmaceuticals a top pick for January 2026. The firm highlighted that CRVS trades at a valuation discount compared to its biotech peers, a gap expected to narrow following the data release. SQL's broader potential in oncology and other immune diseases further supports the higher valuation.

Forward Outlook

Following the strong clinical data, Corvus Pharmaceuticals' stock is positioned for potential growth. Investors will be closely watching future trial developments and the company's progress in capturing market share in the atopic dermatitis space.

FAQ

Q: Why did Mizuho raise the price target for CRVS?
A: Mizuho raised the target due to "outstanding" Phase 1 clinical trial data for soquelitinib, Corvus's drug for atopic dermatitis.

Q: What is the new price target for Corvus Pharmaceuticals?
A: The new price target set by Mizuho is $20.00 per share, up from the previous target of $13.00.

Source: Investing.com